IN2014MN02554A - - Google Patents

Info

Publication number
IN2014MN02554A
IN2014MN02554A IN2554MUN2014A IN2014MN02554A IN 2014MN02554 A IN2014MN02554 A IN 2014MN02554A IN 2554MUN2014 A IN2554MUN2014 A IN 2554MUN2014A IN 2014MN02554 A IN2014MN02554 A IN 2014MN02554A
Authority
IN
India
Prior art keywords
inhibitors
relates
protein kinase
present
tec
Prior art date
Application number
Other languages
English (en)
Inventor
Alain Laurent
Yannick Rose
Original Assignee
Pharmascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmascience Inc filed Critical Pharmascience Inc
Publication of IN2014MN02554A publication Critical patent/IN2014MN02554A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN2554MUN2014 2012-07-06 2013-07-03 IN2014MN02554A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2782774A CA2782774A1 (fr) 2012-07-06 2012-07-06 Inhibiteurs de proteine kinase
PCT/CA2013/000612 WO2014005217A1 (fr) 2012-07-06 2013-07-03 Inhibiteurs de protéines kinases

Publications (1)

Publication Number Publication Date
IN2014MN02554A true IN2014MN02554A (fr) 2015-07-24

Family

ID=49881186

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2554MUN2014 IN2014MN02554A (fr) 2012-07-06 2013-07-03

Country Status (12)

Country Link
US (2) US9447102B2 (fr)
EP (1) EP2870158B1 (fr)
JP (1) JP6190881B2 (fr)
KR (2) KR101903123B1 (fr)
CN (1) CN104718207B (fr)
BR (1) BR112014033056A2 (fr)
CA (2) CA2782774A1 (fr)
ES (1) ES2631228T3 (fr)
HK (1) HK1209726A1 (fr)
IN (1) IN2014MN02554A (fr)
RU (1) RU2679122C2 (fr)
WO (1) WO2014005217A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2782774A1 (fr) * 2012-07-06 2014-01-06 Pharmascience Inc. Inhibiteurs de proteine kinase
CA2833701A1 (fr) * 2013-11-19 2015-05-19 Pharmascience Inc. Inhibiteurs de proteine kinase
CA2833867A1 (fr) * 2013-11-21 2015-05-21 Pharmascience Inc. Inhibiteurs de proteine kinase
CA2834528A1 (fr) * 2013-11-26 2015-05-26 Pharmascience Inc. Inhibiteurs de proteines kinases
CN103787839B (zh) * 2014-01-21 2015-12-02 苏州昊帆生物科技有限公司 合成2,3,4,5,6-五氟苯酚的方法
WO2016187723A1 (fr) * 2015-05-27 2016-12-01 Pharmascience Inc. Inhibiteurs de la famille des enzymes kinases tec
KR20180109842A (ko) * 2015-09-16 2018-10-08 록쏘 온콜로지, 인코포레이티드 화합물
WO2017134685A2 (fr) * 2016-02-02 2017-08-10 Sun Pharma Advanced Research Company Limited Nouveaux composés hydrazino utilisés comme inhibiteurs de btk
EP3492471B1 (fr) 2016-08-17 2020-12-02 Shenzhen TargetRx, Inc. Composé bicyclique fusionné pour inhiber l'activité de la tyrosine kinase
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3736728A1 (de) * 1987-10-29 1989-05-11 Siemens Ag Druckertinte
DE59310344D1 (de) * 1992-09-24 2003-07-24 Hoechst Ag N1-Substituierte 1H-1,2,3-Triazolo[4,5-d]pyrimidine, Verfahren zu ihrer Herstellung sowie ihre Verwendung als antivirale Mittel
JP2003509427A (ja) 1999-09-17 2003-03-11 アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー 治療剤としてのキナーゼ阻害剤
DE10031584A1 (de) * 2000-06-29 2002-01-10 Merck Patent Gmbh 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
US20030199525A1 (en) * 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
JP5347202B2 (ja) * 2007-03-28 2013-11-20 ファーマサイクリックス，インク． ブルトンチロシンキナーゼインヒビター
CA2782774A1 (fr) * 2012-07-06 2014-01-06 Pharmascience Inc. Inhibiteurs de proteine kinase
MX2020009849A (es) * 2012-11-01 2021-09-13 Infinity Pharmaceuticals Inc Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa.

Also Published As

Publication number Publication date
JP6190881B2 (ja) 2017-08-30
WO2014005217A1 (fr) 2014-01-09
CN104718207B (zh) 2017-08-15
EP2870158B1 (fr) 2017-05-31
CA2782774A1 (fr) 2014-01-06
EP2870158A4 (fr) 2015-12-09
JP2015521987A (ja) 2015-08-03
CA2878332C (fr) 2019-04-30
KR101903123B1 (ko) 2018-10-01
ES2631228T3 (es) 2017-08-29
CN104718207A (zh) 2015-06-17
KR20150041784A (ko) 2015-04-17
CA2878332A1 (fr) 2014-01-09
EP2870158A1 (fr) 2015-05-13
US20160375027A1 (en) 2016-12-29
RU2014151421A (ru) 2016-08-27
US9795608B2 (en) 2017-10-24
KR20180107328A (ko) 2018-10-01
US9447102B2 (en) 2016-09-20
US20150344478A1 (en) 2015-12-03
BR112014033056A2 (pt) 2017-06-27
RU2679122C2 (ru) 2019-02-06
HK1209726A1 (en) 2016-04-08

Similar Documents

Publication Publication Date Title
IN2014MN02554A (fr)
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
PH12015501385A1 (en) Autotaxin inhibitors
MX2015013042A (es) Compuestos organicos.
TN2014000516A1 (en) New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12014000179A1 (en) New pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
PH12016500094A1 (en) Autotaxin inhibitors
MX357305B (es) Compuestos y composiciones para inhibir la actividad de abl-1, abl-2, y bcr-abl1.
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
IN2014MN02598A (fr)
MX353806B (es) Quinolinas como moduladores de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr).
PH12016500057A1 (en) Novel indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
EA201590161A1 (ru) Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона
MX343929B (es) Inhibidores de proteina cinasa.
TN2013000400A1 (en) Imidazopyridazines as akt kinase inhibitors
MY166449A (en) Pharmaceutical composition of rosuvastatin calcium
IN2014MN02338A (fr)
GEP20207108B (en) Substituted 2,4 diamino-quinoline as new anticancer agents
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
MX2016000900A (es) Nuevos derivados de indol y de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
IN2015DN00950A (fr)
NI201200102A (es) Procedimiento de síntesis y forma cristalina del hidrocloruro de 4 - { 3 - [ cis - hexahidrociclopenta [c] pirrol - 2 (1h) - il ] propoxi } benzamida así como las composiciones farmacéuticas que la contienen.